Empower Pharmacy Lawsuit Widens as 2026 Claims Target Compounded GLP-1s

What Happened

Civil litigation against Empower Pharmacy has expanded steadily through 2026, and updated claims filed as of September target the Houston-based compounding pharmacy's sale of compounded GLP-1 medications, including semaglutide and tirzepatide. Plaintiffs allege that injectable products distributed by the facility were contaminated, subpotent, or released without adequate sterility and potency testing. The company has disputed some regulatory findings and pledged corrective action on others, but no settlement has been reached and no class has been certified as of mid-2026.

Empower operates as a 503B outsourcing facility, a category held to current Good Manufacturing Practice (cGMP) standards closer to those of a drug manufacturer than a traditional compounding pharmacy. Because 503B facilities produce large batches without individual patient prescriptions, quality failures at this scale can affect thousands of customers at once — the central argument plaintiff firms are now advancing.

Who Is Affected

The claims are concentrated among people who received compounded GLP-1 medications during and after the FDA's semaglutide shortage period. Attorneys describe several categories:

• Patients reporting injection-site infections or allergic reactions
• Buyers who received products later found to be subpotent or incorrectly concentrated
• Customers of telehealth clinics that sourced injectables from Empower
• Consumers pursuing economic claims after paying for products that failed quality expectations

Regulatory filings cited in the litigation include FDA warning letters describing failures in sterility assurance, environmental monitoring, and endotoxin testing for injectable drugs. Follow-up inspections reportedly documented persistent issues, a pattern attorneys argue supports negligence claims.

Timeline

• 2024–2025: FDA issues warning letters citing cGMP violations; the agency removes semaglutide from its shortage list in early 2024, triggering legal disputes over continued compounding
• January 2026: Additional individual injury lawsuits are filed in Texas state courts
• February 2026: Follow-up inspection data shows ongoing compliance concerns
• March 2026: Multiple national plaintiff firms announce case reviews for compounded GLP-1 claims
• Q2 2026: Plaintiff steering committees discuss multidistrict litigation (MDL) consolidation — not yet granted
• September 2026: Claims are updated and expanded; no global settlement or class certification has occurred

What This Means for Researchers

The case is a stress test for the entire compounded injectable market. Litigation of this shape typically turns on batch records, certificates of analysis, and testing documentation — the same documents that separate credible suppliers from poor ones. If MDL consolidation is granted, discovery is likely to surface industry-wide practices around sterility testing and potency verification, raising the documentation bar for every vendor in the category. For research buyers, the practical lesson is that scale does not equal quality: large output volumes magnify, rather than excuse, testing gaps.

How to Verify Your Peptides

Demand a current, batch-specific certificate of analysis from any supplier, and treat missing purity or endotoxin data as a red flag. Our testing library explains what legitimate documentation looks like, starting with our semaglutide purity testing guide and tirzepatide HPLC testing overview.

Safe Alternatives

If your sourcing depends on compounded injectables, review independently documented options first. PepsReview maintains reference pages for semaglutide and tirzepatide, plus a vetted vendor directory with published testing claims and community feedback.

Sources

Regulatory announcements; industry reports; court filing summaries compiled by PepsReview Editorial.